Bharat Moyal: The New KDIGO 2026 Approach to Anemia in CKD
Bharat Moyal, Medical Affairs Fellow at Academically Global, shared a post on LinkedIn:
”KDIGO 2026 Clinical Practice Guideline: A New Era in the Management of Anemia in CKD.
What’s new in the 2026 guideline?
1. A more systematic approach to diagnosis
The guideline emphasizes comprehensive evaluation of anemia and identification of potentially reversible causes, particularly iron deficiency.
2. Updated approach to iron deficiency KDIGO introduces updated terminology:
- Systemic iron deficiency
- Iron-restricted erythropoiesis
This reflects a more precise understanding of iron availability and erythropoiesis in CKD.
3. Individualized iron therapy
The guideline provides updated recommendations for the use of oral and intravenous iron, with treatment decisions guided by iron status, clinical context, benefits, risks, and patient preferences.
4. Reassessment of anemia therapies The 2026 update incorporates newer evidence surrounding:
- Erythropoiesis-stimulating agents (ESAs)
- HIF-prolyl hydroxylase inhibitors (HIF-PHIs)
- Iron therapies
- Red blood cell transfusion strategies
5. ‘Treat the patient, not just the number’ A key theme is individualized anemia management—balancing symptoms, potential benefits, cardiovascular and treatment-related risks, comorbidities, and patient preferences rather than pursuing hemoglobin correction in isolation.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring